tiprankstipranks
Cytokinetics (CYTK)
NASDAQ:CYTK
US Market
CYTK
Cytokinetics
RESEARCH TOOLSreports
Want to see CYTK full AI Analyst Report?

Cytokinetics (CYTK) Stock Forecast & Price Target

1,270 Followers
See the Price Targets and Ratings of:

CYTK Analyst Ratings

Strong Buy
19Ratings
Strong Buy
16 Buy
3 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Cytokinetics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CYTK Stock 12 Month Forecast

Average Price Target

$98.58
▲(47.77% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $98.58 with a high forecast of $140.00 and a low forecast of $67.00. The average price target represents a 47.77% change from the last price of $66.71.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","141":"$141","57.75":"$57.8","85.5":"$85.5","113.25":"$113.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":98.57941176470588,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$98.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$67.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,57.75,85.5,113.25,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.35,69.24615384615385,75.1423076923077,81.03846153846155,86.93461538461538,92.83076923076923,98.72692307692307,104.62307692307692,110.51923076923077,116.41538461538462,122.31153846153848,128.20769230769233,134.10384615384615,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.35,66.05995475113123,68.76990950226245,71.47986425339367,74.18981900452489,76.89977375565611,79.60972850678733,82.31968325791856,85.02963800904978,87.739592760181,90.44954751131222,93.15950226244344,95.86945701357466,{"y":98.57941176470588,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.35,63.63076923076923,63.91153846153846,64.1923076923077,64.47307692307692,64.75384615384615,65.03461538461539,65.31538461538462,65.59615384615384,65.87692307692308,66.15769230769232,66.43846153846154,66.71923076923076,{"y":67,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.92,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.21,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.84,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.43,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.61,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.35,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$140.00Average Price Target$98.58Lowest Price Target$67.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on CYTK
Maxwell Skor
Morgan Stanley
Morgan Stanley
$103→$75.85
Buy
13.70%
Upside
Reiterated
05/18/26
Morgan Stanley Sticks to Its Buy Rating for Cytokinetics (CYTK)
H.C. Wainwright Analyst forecast on CYTK
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$140
Buy
109.86%
Upside
Reiterated
05/12/26
Cytokinetics price target raised to $140 from $136 at H.C. WainwrightCytokinetics price target raised to $140 from $136 at H.C. Wainwright
J.P. Morgan Analyst forecast on CYTK
Tessa Romero
J.P. Morgan
J.P. Morgan
$92→$97
Buy
45.41%
Upside
Assigned
05/12/26
Cytokinetics price target raised to $97 from $92 at JPMorganCytokinetics price target raised to $97 from $92 at JPMorgan
Wells Fargo Analyst forecast on CYTK
Yanan Zhu
Wells Fargo
Wells Fargo
$95→$105
Buy
57.40%
Upside
Reiterated
05/07/26
Cytokinetics (CYTK) Gets a Buy from Wells Fargo
Raymond James Analyst forecast on CYTK
Unknown Analyst
Raymond James
Not Ranked
Raymond James
―
Hold
―
Reiterated
05/06/26
Raymond James Reaffirms Their Hold Rating on Cytokinetics (CYTK)
Piper Sandler Analyst forecast on CYTK
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$107
Buy
60.40%
Upside
Reiterated
05/06/26
Piper Sandler Reaffirms Their Buy Rating on Cytokinetics (CYTK)
Truist Financial Analyst forecast on CYTK
Srikripa Devarakonda
Truist Financial
Truist Financial
$92→$106
Buy
58.90%
Upside
Reiterated
05/06/26
Cytokinetics price target raised to $106 from $92 at TruistCytokinetics price target raised to $106 from $92 at Truist
Needham Analyst forecast on CYTK
Serge Belanger
Needham
Needham
$102
Buy
52.90%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Repligen (NASDAQ: RGEN), Disc Medicine (NASDAQ: IRON) and Cytokinetics (NASDAQ: CYTK)
Stifel Nicolaus Analyst forecast on CYTK
James Condulis
Stifel Nicolaus
Stifel Nicolaus
$98→$108
Buy
61.89%
Upside
Assigned
05/06/26
Cytokinetics price target raised to $108 from $98 at StifelCytokinetics price target raised to $108 from $98 at Stifel
RBC Capital Analyst forecast on CYTK
Leonid Timashev
RBC Capital
RBC Capital
$101→$119
Buy
78.38%
Upside
Reiterated
05/05/26
RBC Capital Reaffirms Their Buy Rating on Cytokinetics (CYTK)
Goldman Sachs Analyst forecast on CYTK
Paul Choi
Goldman Sachs
Goldman Sachs
$101
Buy
51.40%
Upside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Strata Critical Medical (NASDAQ: SRTA) and Cytokinetics (NASDAQ: CYTK)
Bank of America Securities Analyst forecast on CYTK
Jason Zemansky
Bank of America Securities
Bank of America Securities
$67
Hold
0.43%
Upside
Reiterated
04/30/26
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (NASDAQ: MBX), Cytokinetics (NASDAQ: CYTK) and Crescent Biopharma (NASDAQ: CBIO)
Barclays Analyst forecast on CYTK
Emily Field
Barclays
Barclays
$87→$95
Buy
42.41%
Upside
Assigned
04/06/26
Barclays Remains a Buy on Cytokinetics (CYTK)
Evercore ISI Analyst forecast on CYTK
Cory Kasimov
Evercore ISI
Evercore ISI
$80
Buy
19.92%
Upside
Reiterated
04/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on CYTK
Ashwani Verma
UBS
UBS
$61→$69
Hold
3.43%
Upside
Reiterated
03/24/26
Analysts Conflicted on These Healthcare Names: Cytokinetics (NASDAQ: CYTK), Aardvark Therapeutics, Inc. (NASDAQ: AARD) and Incyte (NASDAQ: INCY)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on CYTK
Maxwell Skor
Morgan Stanley
Morgan Stanley
$103→$75.85
Buy
13.70%
Upside
Reiterated
05/18/26
Morgan Stanley Sticks to Its Buy Rating for Cytokinetics (CYTK)
H.C. Wainwright Analyst forecast on CYTK
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$140
Buy
109.86%
Upside
Reiterated
05/12/26
Cytokinetics price target raised to $140 from $136 at H.C. WainwrightCytokinetics price target raised to $140 from $136 at H.C. Wainwright
J.P. Morgan Analyst forecast on CYTK
Tessa Romero
J.P. Morgan
J.P. Morgan
$92→$97
Buy
45.41%
Upside
Assigned
05/12/26
Cytokinetics price target raised to $97 from $92 at JPMorganCytokinetics price target raised to $97 from $92 at JPMorgan
Wells Fargo Analyst forecast on CYTK
Yanan Zhu
Wells Fargo
Wells Fargo
$95→$105
Buy
57.40%
Upside
Reiterated
05/07/26
Cytokinetics (CYTK) Gets a Buy from Wells Fargo
Raymond James Analyst forecast on CYTK
Unknown Analyst
Raymond James
Not Ranked
Raymond James
―
Hold
―
Reiterated
05/06/26
Raymond James Reaffirms Their Hold Rating on Cytokinetics (CYTK)
Piper Sandler Analyst forecast on CYTK
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$107
Buy
60.40%
Upside
Reiterated
05/06/26
Piper Sandler Reaffirms Their Buy Rating on Cytokinetics (CYTK)
Truist Financial Analyst forecast on CYTK
Srikripa Devarakonda
Truist Financial
Truist Financial
$92→$106
Buy
58.90%
Upside
Reiterated
05/06/26
Cytokinetics price target raised to $106 from $92 at TruistCytokinetics price target raised to $106 from $92 at Truist
Needham Analyst forecast on CYTK
Serge Belanger
Needham
Needham
$102
Buy
52.90%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Repligen (NASDAQ: RGEN), Disc Medicine (NASDAQ: IRON) and Cytokinetics (NASDAQ: CYTK)
Stifel Nicolaus Analyst forecast on CYTK
James Condulis
Stifel Nicolaus
Stifel Nicolaus
$98→$108
Buy
61.89%
Upside
Assigned
05/06/26
Cytokinetics price target raised to $108 from $98 at StifelCytokinetics price target raised to $108 from $98 at Stifel
RBC Capital Analyst forecast on CYTK
Leonid Timashev
RBC Capital
RBC Capital
$101→$119
Buy
78.38%
Upside
Reiterated
05/05/26
RBC Capital Reaffirms Their Buy Rating on Cytokinetics (CYTK)
Goldman Sachs Analyst forecast on CYTK
Paul Choi
Goldman Sachs
Goldman Sachs
$101
Buy
51.40%
Upside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Strata Critical Medical (NASDAQ: SRTA) and Cytokinetics (NASDAQ: CYTK)
Bank of America Securities Analyst forecast on CYTK
Jason Zemansky
Bank of America Securities
Bank of America Securities
$67
Hold
0.43%
Upside
Reiterated
04/30/26
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (NASDAQ: MBX), Cytokinetics (NASDAQ: CYTK) and Crescent Biopharma (NASDAQ: CBIO)
Barclays Analyst forecast on CYTK
Emily Field
Barclays
Barclays
$87→$95
Buy
42.41%
Upside
Assigned
04/06/26
Barclays Remains a Buy on Cytokinetics (CYTK)
Evercore ISI Analyst forecast on CYTK
Cory Kasimov
Evercore ISI
Evercore ISI
$80
Buy
19.92%
Upside
Reiterated
04/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on CYTK
Ashwani Verma
UBS
UBS
$61→$69
Hold
3.43%
Upside
Reiterated
03/24/26
Analysts Conflicted on These Healthcare Names: Cytokinetics (NASDAQ: CYTK), Aardvark Therapeutics, Inc. (NASDAQ: AARD) and Incyte (NASDAQ: INCY)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cytokinetics

3 Months
Tessa RomeroJ.P. Morgan
Success Rate
14/23 ratings generated profit
61%
Average Return
+26.23%
Copying Tessa Romero's trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +26.23% per trade.
1 Year
Joseph PantginisH.C. Wainwright
Success Rate
17/18 ratings generated profit
94%
Average Return
+43.87%
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 94.44% of your transactions generating a profit, with an average return of +43.87% per trade.
2 Years
Yasmeen RahimiPiper Sandler
Success Rate
18/19 ratings generated profit
95%
Average Return
+47.62%
Copying Yasmeen Rahimi's trades and holding each position for 2 Years would result in 94.74% of your transactions generating a profit, with an average return of +47.62% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CYTK Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
14
16
16
12
12
Buy
27
29
20
20
19
Hold
5
6
7
7
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
46
51
43
39
37
In the current month, CYTK has received 31 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. CYTK average Analyst price target in the past 3 months is 98.58.
Each month's total comprises the sum of three months' worth of ratings.

CYTK Financial Forecast

CYTK Earnings Forecast

Next quarter’s earnings estimate for CYTK is -$1.63 with a range of -$2.02 to -$1.26. The previous quarter’s EPS was -$1.67. CYTK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CYTK has Performed in-line its overall industry.
Next quarter’s earnings estimate for CYTK is -$1.63 with a range of -$2.02 to -$1.26. The previous quarter’s EPS was -$1.67. CYTK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CYTK has Performed in-line its overall industry.

CYTK Sales Forecast

Next quarter’s sales forecast for CYTK is $16.74M with a range of $7.00M to $27.71M. The previous quarter’s sales results were $19.36M. CYTK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CYTK has Performed in-line its overall industry.
Next quarter’s sales forecast for CYTK is $16.74M with a range of $7.00M to $27.71M. The previous quarter’s sales results were $19.36M. CYTK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CYTK has Performed in-line its overall industry.

CYTK Stock Forecast FAQ

What is CYTK’s average 12-month price target, according to analysts?
Based on analyst ratings, Cytokinetics’s 12-month average price target is 98.58.
    What is CYTK’s upside potential, based on the analysts’ average price target?
    Cytokinetics has 47.77% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CYTK a Buy, Sell or Hold?
          Cytokinetics has a consensus rating of Strong Buy which is based on 16 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Cytokinetics’s price target?
            The average price target for Cytokinetics is 98.58. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $140.00 ,the lowest forecast is $67.00. The average price target represents 47.77% Increase from the current price of $66.71.
              What do analysts say about Cytokinetics?
              Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of CYTK?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.